跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
泰毕安 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Idarucizumab Injection
Approved
生物制品
Idarucizumab Injection
Boehringer Ingelheim International GmbH
🇨🇳 National Medical Products Administration
Approval Date
Dec 22, 2022
Approval ID
1xpZwrDCZgw
Company
Boehringer Ingelheim International GmbH
Type
生物制品
Approval Details
Approval Id
1xpZwrDCZgw
Approval Number
国药准字SJ20180012
Generic Name
依达赛珠单抗注射液
Generic Name En
Idarucizumab Injection
Trade Name
泰毕安
Drug Type
生物制品
Dosage Form
注射剂
Strength
2.5g/50mL
Reg Date
2022-12-22
Expired Date
2027-12-21
Company Name
Boehringer Ingelheim International GmbH
Production Company Name
Boehringer Ingelheim Pharma GmbH & Co. KG
Company Detail Path
/organization/boehringer-ingelheim-international-gmbh
Production Company Detail Path
/organization/boehringer-ingelheim-pharma-gmbh-and-co-kg
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Dec 22, 2022
Approval ID
1xpZwrDCZgw
Type
生物制品
Back to NMPA Approvals